lifestyle.massnews.com

Author: Cardiff Oncology, Inc.

Cardiff Oncology Presents Preclinical Data on its PLK1 Inhibitor Onvansertib in Combination with a HER2-Targeted ADC at the 2026 AACR Annual Meeting

April 17, 2026
Cardiff Oncology to Host Key Opinion Leader Discussion Focusing on First-Line RAS-mutated Metastatic Colorectal Cancer

March 20, 2026
Cardiff Oncology to Present Preclinical Data with Highly Specific PLK1 Inhibitor Onvansertib at the 2026 AACR Annual Meeting

March 19, 2026
Cardiff Oncology to Participate in Three Upcoming Investor Conferences

February 26, 2026
Cardiff Oncology Reports Full Year 2025 Results and Provides Business Update

February 25, 2026
Cardiff Oncology to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference

February 19, 2026
Cardiff Oncology Announces Executive Leadership Changes as it Transitions to Late-Stage Clinical Development

January 27, 2026
Cardiff Oncology Announces Positive Update from its Randomized Phase 2 Trial of Onvansertib in First-line RAS-mutated mCRC

January 27, 2026